Friday, 15 May 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 15 May 2026
News

AZ scrambles to shift $17M market

Posted 15 May 2026 AM

A global decision by AstraZeneca to reduce the number of dose options of gonadotropin-releasing hormone agonist Zoladex has its local arm striving to ensure patients can maintain treatment.

The 3.6mg dose option of Zoladex is being discontinued from November this year, leaving only the 10.8mg dose funded on the PBS. However while the 3.6mg dose is indicated for prostate cancer, breast cancer, endometriosis, uterine fibroids, endometrial thinning, and assisted reproduction, the 10.8mg dose is only approved for prostate cancer.

To see the whole article, please login

Popular

What cardiologists think of Reps
'Ignored': Pharma fury at Budget fail
Pharma crowned 'Most Impactful'
Where's the action? Patients ask
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home